Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stella Bowcock

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
European Journal of Haematology|October 10, 2020
Survival trends in elderly myeloma patientsAdam Jones, Stella Bowcock, Bernard Rachet
Plos One|October 19, 2022
High numbers of COVID-19 patients transit through non-COVID wards, and associated healthcare workers have high infection rates: An observational cross-sectional studySusanna Nallamilli, Tejus Patel, April Buazon, et al.
Frontiers in Oncology|December 15, 2023
Patient-reported symptoms and diagnostic journey in Multiple MyelomaRohit Vijjhalwar, Kaiyang Song, Roshi Shrestha, et al.
British Journal of Haematology|May 20, 2026
Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imagingAidan Haslam, Gulnaz Iqbal, Mark Drayson, et al.
British Journal of Haematology|January 21, 2017
Guidelines for screening and management of late and long-term consequences of myeloma and its treatmentJohn A Snowden, Diana M Greenfield, Jennifer M Bird, et al.
Leukemia & Lymphoma|January 18, 2017
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre studyVijay Dhanapal, Menaka Gunasekara, Chia Lianwea, et al.
Blood Cancer Journal|November 5, 2020
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient managementIlaria J Chicca, Jennifer L J Heaney, Gulnaz Iqbal, et al.
Value in Health Regional Issues|February 25, 2023
An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United KingdomAlex Porteous, Scott Gibson, Lucy A Eddowes, et al.
British Journal of Haematology|August 17, 2020
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trialCatherine Atkin, Gulnaz Iqbal, Tim Planche, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 26, 2026
Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD datasetRohit Vijjhalwar, Kaiyang Song, Franz Clemeno, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
European Journal of Haematology|October 10, 2020
Survival trends in elderly myeloma patientsAdam Jones, Stella Bowcock, Bernard Rachet
Plos One|October 19, 2022
High numbers of COVID-19 patients transit through non-COVID wards, and associated healthcare workers have high infection rates: An observational cross-sectional studySusanna Nallamilli, Tejus Patel, April Buazon, et al.
Frontiers in Oncology|December 15, 2023
Patient-reported symptoms and diagnostic journey in Multiple MyelomaRohit Vijjhalwar, Kaiyang Song, Roshi Shrestha, et al.
British Journal of Haematology|May 20, 2026
Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imagingAidan Haslam, Gulnaz Iqbal, Mark Drayson, et al.
British Journal of Haematology|January 21, 2017
Guidelines for screening and management of late and long-term consequences of myeloma and its treatmentJohn A Snowden, Diana M Greenfield, Jennifer M Bird, et al.
Leukemia & Lymphoma|January 18, 2017
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre studyVijay Dhanapal, Menaka Gunasekara, Chia Lianwea, et al.
Blood Cancer Journal|November 5, 2020
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient managementIlaria J Chicca, Jennifer L J Heaney, Gulnaz Iqbal, et al.
Value in Health Regional Issues|February 25, 2023
An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United KingdomAlex Porteous, Scott Gibson, Lucy A Eddowes, et al.
British Journal of Haematology|August 17, 2020
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trialCatherine Atkin, Gulnaz Iqbal, Tim Planche, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 26, 2026
Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD datasetRohit Vijjhalwar, Kaiyang Song, Franz Clemeno, et al.
Pageof 2